Summary This latest Pharmaceutical and Healthcare disease pipeline guide Narcolepsy - Pipeline Review, H2 2020, provides an overview of the Narcolepsy (Central Nervous System) pipeline landscape.
Narcolepsy is a sleep disorder that causes excessive sleepiness and frequent daytime sleep attacks. Symptoms of narcolepsy include excessive daytime sleepiness (EDS), cataplexy, hallucinations and sleep paralysis. Narcolepsy treatment includes lifestyle change, medication and counseling.
Report Highlights Pharmaceutical and Healthcare latest pipeline guide Narcolepsy - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Narcolepsy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Narcolepsy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Narcolepsy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 7, 5, 5 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Narcolepsy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Narcolepsy (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Narcolepsy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Narcolepsy (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Narcolepsy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Narcolepsy (Central Nervous System)
Reasons to Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Narcolepsy (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Narcolepsy (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Our reports have been used by over 10K customers, including:
Ischemia Reperfusion Injury Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary This latest Pharmaceutical and Healthcare disease pipeline guide Ischemia Reperfusion Injury - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key...
Toll Like Receptor 3 (CD283 or TLR3) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Toll Like Receptor 3 (CD283 or TLR3) - Toll-like receptor 3 (TLR3) is a protein encoded by the TLR3 gene. It controls host immune response against...
Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary According to the recently published report ’Bromodomain Containing Protein 3 - Drugs In Development, 2022’; Bromodomain...
Oral Mucositis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary This latest Pharmaceutical and Healthcare disease pipeline guide Oral Mucositis - Drugs In Development, 2022, provides an overview of the Oral Mucositis (Gastrointestinal) pipeline...
Cell Division Protein FtsZ (ftsz) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Cell Division Protein FtsZ (ftsz) pipeline Target constitutes close to 7 molecules. Out of which approximately 2 molecules are developed by...
120 pages •
By Infiniti Research Limited
• Apr 2022
Global Cytomegalovirus (CMV) Therapeutics Market 2022-2026 The analyst has been monitoring the cytomegalovirus (CMV) therapeutics market and it is poised to grow by $ 332.21 mn during 2022-2026, accelerating at a CAGR of 5.44% during the forecast period. Our report on the cytomegalovirus (CMV) therapeutics market provides...
120 pages •
By Infiniti Research Limited
• Apr 2022
Global Plasma Therapeutics Market 2022-2026 The analyst has been monitoring the plasma therapeutics market and it is poised to grow by $ 8.98 bn during 2022-2026 progressing at a CAGR of 6.1% during the forecast period. Our report on the plasma therapeutics market provides a holistic analysis, market size and forecast,...
Non-Alcoholic Steatohepatitis (NASH) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary This latest Pharmaceutical and Healthcare disease pipeline guide Non-Alcoholic Steatohepatitis (NASH) - Drugs in Development by Stages, Target, MoA, RoA, Molecule...
350 pages •
By Roots Analysis Private Ltd.
• Mar 2022
INTRODUCTION Post the approval of the first aptamer-based therapy, Macugen®, by the US Food and Drug Administration (USFDA) in December 2004, there has been a significant increase in the R&D initiatives focused on evaluating the potential of aptamers as theranostic agents. In the following year, the outstanding annual sales...
651 pages •
By IQ4I Research & Consultancy Pvt. Ltd
• Mar 2022
Over the past 50 years, the nuclear medicine field has displayed a strong link between investments in chemistry and the development of radionuclide and radio-labeled compounds which have impacted the healthcare practice. Nuclear medicine comprises diagnostic and therapeutic techniques that use radioisotopes for applications...
Therapy
Oncology
Diagnostics
United States
World
PET Production
By continuing to use this site you consent to the use of cookies on your device as described in our Cookie Policy unless you have disabled them.
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.